Candel Therapeutics, Inc. 8-K

What Happened
Candel Therapeutics, Inc. filed an 8-K on June 16, 2026 disclosing an employment agreement dated June 12, 2026 with its Chief Financial Officer, Charles Schoch. The agreement continues Mr. Schoch’s at‑will employment, sets his annual base salary at $468,600 and maintains eligibility for an annual bonus with a 40% target. The filing includes severance and health‑coverage continuation terms if Schoch is terminated by the company without “cause” or resigns for “good reason,” plus equity acceleration around a change in control.

Key Details

• Base salary: $468,600 per year; annual bonus target: 40% of base salary.
• Severance: if terminated without “cause” or for “good reason,” subject to a release, entitles him to nine months of base salary plus the target annual bonus, paid over nine months.
• Health coverage: company will continue to pay its share of premiums for up to nine months (subject to COBRA rules and earlier eligibility under another employer plan).
• Equity: all time‑based equity awards fully accelerate if termination without “cause” or for “good reason” occurs within one month before or 12 months after a change in control.
• Agreement includes customary confidentiality, non‑competition and non‑solicitation provisions; full agreement is attached as Exhibit 10.1.

Why It Matters
This filing confirms the company’s efforts to retain its CFO and describes potential cash and equity costs tied to severance and change‑in‑control scenarios. For investors, the material points are the fixed compensation level, the defined severance exposure (nine months pay plus bonus), and the possible acceleration of time‑based equity—which could affect dilution and compensation expense in the event of a change in control or qualifying termination. The agreement does not report a departure; it documents continued employment under specified terms.